FORT WORTH, Texas, Aug. 12 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., , announced today the publication of (2) independent case reports utilizing their advanced wound care collagen product, CellerateRx(R), in the August edition of Advances in Skin and Wound Care. The case presentations were on recalcitrant diabetic wounds. "Many factors have been implicated in the problematic nature of diabetic wounds to the lower extremities," states Cathy Bradshaw, President of Wound Care Innovations. "We are delighted that the authors' experience with CellerateRx(R) has been a positive one." Diabetic foot ulcers are a common complication of diabetes and affect approximately 15% of the diabetic population.(1) "Management of diabetic wounds is one of the most important challenges in healthcare today both in terms of quality of life for the patient and the economic burden on the system."
Reprints of the article may be obtained by calling Wound Care Innovations at 954-315-9242 or will be available at our website, www.celleraterx.com .
About Wound Management Technologies, Inc.: Wound Management Technologies, Inc. , with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company's Website at www.celleraterx.com .
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
(1) National Diabetes Information Clearinghouse, Diabetes in America, 2nd Edition
CONTACT: Product Information, Cathy Bradshaw, President, +1-954-315- 9242;
or Shareholder Relations, Lucy Singleton, Secretary, +1-817-820-7080, both
of Wound Management Technologies, Inc.
Web site: http://www.celleraterx.com/
